BMO Capital on Alnylam Pharmaceuticals (ALNY): 'Strong ATTR Outlook With Limited Readthrough From Eplontersen'
August 31, 2026 8:57 AM
BMO Capital analyst David Lebowitz reiterated an Outperform rating and $318.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).The analyst commented ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
